- Home
- IMRX vs LPTX Comparison
IMRX vs LPTX Comparison
Compare IMRX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- LPTX
- Stock Information
- Founded
- IMRX 2008
- LPTX 2011
- Country
- IMRX United States
- LPTX United States
- Employees
- IMRX 54
- LPTX N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMRX Health Care
- LPTX Health Care
- Exchange
- IMRX Nasdaq
- LPTX Nasdaq
- Market Cap
- IMRX 145.7M
- LPTX 119.6M
- IPO Year
- IMRX 2021
- LPTX N/A
- Fundamental
- Price
- IMRX $4.24
- LPTX $0.33
- Analyst Decision
- IMRX Strong Buy
- LPTX Hold
- Analyst Count
- IMRX 4
- LPTX 1
- Target Price
- IMRX $13.25
- LPTX N/A
- AVG Volume (30 Days)
- IMRX 3.1M
- LPTX 3.3M
- Earning Date
- IMRX 08-05-2025
- LPTX 08-11-2025
- Dividend Yield
- IMRX N/A
- LPTX N/A
- EPS Growth
- IMRX N/A
- LPTX N/A
- EPS
- IMRX N/A
- LPTX N/A
- Revenue
- IMRX N/A
- LPTX N/A
- Revenue This Year
- IMRX N/A
- LPTX N/A
- Revenue Next Year
- IMRX N/A
- LPTX N/A
- P/E Ratio
- IMRX N/A
- LPTX N/A
- Revenue Growth
- IMRX N/A
- LPTX N/A
- 52 Week Low
- IMRX $1.00
- LPTX $0.22
- 52 Week High
- IMRX $4.60
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- IMRX 77.22
- LPTX 48.69
- Support Level
- IMRX $3.31
- LPTX $0.28
- Resistance Level
- IMRX $4.60
- LPTX $0.36
- Average True Range (ATR)
- IMRX 0.43
- LPTX 0.04
- MACD
- IMRX 0.12
- LPTX 0.01
- Stochastic Oscillator
- IMRX 96.10
- LPTX 39.43
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .